{"id":3906,"date":"2026-10-26T09:00:00","date_gmt":"2026-10-26T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3906"},"modified":"2026-10-26T19:30:32","modified_gmt":"2026-10-26T23:30:32","slug":"pd-1-monotherapy-lengthens-pfs-in-dmmr-endometrial-cancer","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3906","title":{"rendered":"PD 1 Monotherapy Lengthens PFS in dMMR Endometrial Cancer"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Merck<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 results and publication<\/p>\n

Modality<\/strong><\/p>\n

Anti-PD-1 antibody<\/p>\n

Asset<\/strong><\/p>\n

Pembrolizumab (KEYNOTE-C93)<\/p>\n

Target<\/strong><\/p>\n

PD-1<\/p>\n

Disease Area<\/strong><\/p>\n

Mismatch-repair-deficient advanced or recurrent endometrial cancer<\/p>\n

Summary<\/h4>\n

Global Phase III KEYNOTE-C93 data presented and published online 26 October show markedly longer progression-free survival with pembrolizumab alone than carboplatin\u2013paclitaxel in untreated or recurrent mismatch-repair-deficient advanced endometrial cancer. Overall survival has not yet shown a statistically significant difference.<\/p>\n

The trial randomized 299 patients. At 36.7 months median follow-up, median PFS was 38.2 versus 8.4 months (HR 0.57, 95% CI 0.42\u20130.79; P=0.0002), with 36-month PFS of 52.8% versus 30.0%. OS HR was 0.77 (95% CI 0.52\u20131.15; P=0.10), and 36-month OS was 70.7% versus 62.0%. Response rates were 64.1% and 62.1%; 24-month response durability was 77.0% versus 41.3%. Grade-3-or-higher treatment-related adverse events were 18.1% versus 50.7%, while severe immune-mediated events or infusion reactions were 7.4% versus 3.5%.<\/p>\n

Deep Analysis<\/h4>\n

The striking median PFS contrast appears driven more by durable disease control than response frequency, consistent with the prolonged tail of checkpoint benefit in dMMR tumors. Randomization and long follow-up strengthen the disease-control finding. But chemotherapy alone is not the present combination standard everywhere: pembrolizumab plus carboplatin\u2013paclitaxel is an established regimen in advanced endometrial cancer, so this trial does not answer whether monotherapy is noninferior to immunochemotherapy or which patients need upfront cytotoxic treatment. Immune toxicities can be enduring despite fewer aggregate severe treatment-related events. The OS confidence interval includes both benefit and no effect, and later therapy may matter. Mismatch-repair testing reproducibility, disease burden and symptomatic urgency are key selection issues. A future regulator discussion should not be confused with an approved first-line monotherapy indication.<\/p>\n

Company and Product Background<\/h4>\n

Pembrolizumab blocks PD-1 to restore antitumor T-cell activity. Defective DNA mismatch repair raises tumor mutation and neoantigen load, often increasing checkpoint sensitivity. The tested population had advanced or recurrent endometrial cancer and no prior systemic chemotherapy for this setting.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> dMMR biology allows durable chemotherapy-free control for many patients; PFS and duration-of-response data support it.<\/li>\n
  • Interpretation B:<\/strong> chemotherapy contributes early disease control for high-burden patients and the chemotherapy-only comparator overstates displacement of current immunochemotherapy; similar response rates and absent OS significance support caution.<\/li>\n
  • Upgrade:<\/strong> direct comparison or robust sequencing data against immunochemotherapy, mature OS and patient-reported outcomes. Downgrade:<\/strong> excess early progression in high-burden subgroups. Falsification:<\/strong> a contemporary head-to-head study shows clinically important loss of survival with monotherapy.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: KEYNOTE-C93 strengthens a chemotherapy-sparing option for selected dMMR patients, but does not establish that pembrolizumab alone should replace current immunochemotherapy broadly.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: positive for PFS and treatment-event burden; OS uncertain. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Global Phase III KEYNOTE-C93 data presented and published online 26 October show markedly longer progression-free survival with pembrolizumab alone than carboplatin\u2013paclitaxel in untreated or recurrent mismatch-repair-deficient advanced endometrial cancer. Overall survival has not yet…<\/p>\n","protected":false},"author":1,"featured_media":3915,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1218,244,123,522,1107],"class_list":["post-3906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-dmmr","tag-endometrial-cancer","tag-merck","tag-pembrolizumab","tag-phase-3"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3906"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3906\/revisions"}],"predecessor-version":[{"id":3922,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3906\/revisions\/3922"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3915"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}